All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in Atlanta, GA, on 9–12 December 2017. On December 9th, an oral abstract session was held on “Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma, New Therapies”. This session was moderated by Jonathon B Cohen, Emory University - Winship Cancer Institute and Craig A. Portell, University of Virginia.
Abstract #155 was presented during this session, titled “Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase II ACE-LY-004 Study” by Michael Wang, MD, Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX and colleagues. This article is based on data presented at the live session, which may supersede information in the pre-published ASH Abstract.
The authors noted that acalabrutinib monotherapy was found to have a good safety profile with a high ORR. Acalabrutinib’s pharmacokinetic and selectivity profiles allow twice-daily dosing with minimal off-target effects, while achieving near complete and continuous BTK inhibition over time. Additionally, the median DOR, PFS and OS was not reached, which they suggested showed good duration of treatment response.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox